Condition
CAR-T Cell Immunotherapy
Total Trials
4
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 1 (4)
Trial Status
Withdrawn4
Clinical Trials (4)
Showing 4 of 4 trials
NCT03252171Phase 1Withdrawn
CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients
NCT02575261Phase 1Withdrawn
CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients
NCT04406610Phase 1Withdrawn
CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients
NCT02723942Phase 1Withdrawn
CAR-T Cell Immunotherapy for HCC Targeting GPC3
Showing all 4 trials